Lonza Group (LZAGY) Stock Forecast & Price Target

Lonza Group
Bull Case

Here are some ways that investors could benefit from investing in Lonza Group AG:

• Lonza Group AG demonstrated strong financial performance in the first half of 2026, achieving 16% sales growth and a 44% increase in net profit, which indicates robust operational efficiency and demand for its contract development and manufacturing services.
• The company raised its 2026 CORE EBITDA margin outlook to 33-34% while maintaining guidance for 11-12% sales growth, signaling management confidence in sustained profitability and the ability to convert revenue growth into higher earnings.
• Key segments including Integrated Biologics, Advanced Synthesis, and Specialized Modalities each delivered double-digit growth, highlighting broad-based demand across Lonza Group AG's core business areas and reducing reliance on any single product line.
• The divestment of the Capsules and Health Ingredients business accelerates Lonza Group AG's transition to a pure-play CDMO, which improves capital allocation visibility and allows the company to focus resources on higher-margin pharmaceutical and biotech manufacturing.
• With the current stock price at $69.98, Lonza Group AG trades below its 52-week high of $74.36, offering a potential entry point for investors who believe the recent guidance increases and structural growth tailwinds will drive further appreciation.